This from Seeking Alpha...... “Sarepta Therapeutics has seen a...

This from Seeking Alpha......

“Sarepta Therapeutics has seen a great 2017 and projects sales to nearly double again in 2018.
The company is doing great work on Duchenne, but its approval is still limited in the total patient population, as greater geographical coverage can be beneficial as well.
Shares have priced in a great deal of good news already last year, but I am still appealed to the shares.
Respectful of the momentum seen already, I am eager to buy on significant dips.”
.........................
Sarepta from the article above will be looking at increasing its treatment for the greater DMD population......
Anp to attract this interest when we get the green light to start our trial on inflammation Dmd....